Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, along with gemcitabine/ABRAXANE (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE versus gemcitabine/ABRAXANE for patients with metastatic pancreatic cancer.

Trial Profile

A Phase II, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, along with gemcitabine/ABRAXANE (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE versus gemcitabine/ABRAXANE for patients with metastatic pancreatic cancer.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 10 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Indoximod (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms Indigo201
  • Sponsors New Links Genetics Corporation
  • Most Recent Events

    • 03 May 2018 According to a NewLink Genetics Corporation media release, data from this trial will be presented at the ASCO Annual Meeting, June 2018
    • 02 Nov 2017 According to a NewLink Genetics Corporation media release, the company expects to initiate this trial in the first half of 2018.
    • 28 Sep 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top